Catalent investing $5m to bolster early development offering

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/lovelyday12)
(Image: Getty/lovelyday12)
Catalent plans to invest $5m to create a new drug development center of excellence focusing on preclinical to clinical phase IIb formulation, analytical, and manufacturing solutions.

The delivery technologies and development solutions provider this week announced the investment, which will establish its Somerset, NJ facility and headquarters as a center of excellence (CoE) focused on early phase formulation, analytical, and manufacturing solutions for orally delivered small molecules.

“There is a big trend in the industry where the molecules are getting more and more complex, both on the development side and the manufacturing side,” ​said Elliott Berger, VP of global marketing and strategy at Catalent.

“They need more expertise, they need more technology, they need more focus to get them through the system so they don’t fail for formulation purposes,” ​he explained. “There are plenty of other problems to overcome in this industry; you don’t need to fail for formulation purposes​.”

Catalent is currently working on the expansion plans, Berger told us at CPhI North America, explaining that the company needs “some additional pilot-scale equipment [and] some additional lab equipment.”

“We also need some additional expertise to move these molecules around faster through the process,”​ he added.

However, the company is going to start talking to customers before any plans are solidified. Berger said: “We didn’t want to do a lot of planning until we talked to all the customers. Some of the stuff needs to be done in conjunction with the customer and we want to make sure we do it in a way that they would like it done.”

According to the company, the investment also will build on the site’s modified release formulation development capabilities, bioavailability solutions, and its application of OptiMelt hot melt extrusion (HME) technology.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more